(Q30307998)

English

Infliximab

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 June 2017

1 reference

Europe PubMed Central

Infliximab (English)

1 reference

Europe PubMed Central

16 June 2017

author name string

Valle E

1

1 reference

Europe PubMed Central

16 June 2017

Gross M

2

1 reference

Europe PubMed Central

16 June 2017

Bickston SJ

3

1 reference

Europe PubMed Central

16 June 2017

language of work or name

0 references

publication date

1 June 2001

1 reference

Europe PubMed Central

16 June 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

16 June 2017

2

1 reference

Europe PubMed Central

16 June 2017

6

1 reference

Europe PubMed Central

16 June 2017

1015-1025

1 reference

Europe PubMed Central

16 June 2017

Role of cytokines in the pathogenesis of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Proinflammatory cytokines

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

New medications for use in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Medical therapy for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Cytokine blockade as a new strategy to treat rheumatoid arthritis: inhibition of tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Immunotherapy of Crohn's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Advances in the management of Crohn's disease: economic and clinical potential of infliximab.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

The relationship between infliximab treatment and lymphoma in Crohn's disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Therapeutic monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.6.1015

21 January 2018

Identifiers

10.1517/14656566.2.6.1015

1 reference

Europe PubMed Central

16 June 2017

1 reference

Europe PubMed Central

16 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30307998&oldid=2041857936"